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March 21, 2006:1226–38ize measurement is well-established (4) on the basis of multiple
ines of scientific evidence. We agree that myocardium at risk is
ighly variable and a major determinant of infarct size in both
nimal models and humans. The absence of measurement of
yocardium at risk will reduce power (i.e., increase the likelihood
f a type II [beta] statistical error). However, the estimates
eported in our paper of a type I (alpha) statistical error for infarct
ize remain valid. In the AMISTAD I study (5), myocardium at
isk was measured in a subset of patients. In anterior infarcts,
denosine showed similar benefit using either myocardial salvage
ndex (p  0.015) or infarct size (p  0.014). Other randomized
rials that have measured myocardium at risk and infarct size (6,7)
ave reported similar significant differences using either infarct size
r salvage index as an end point.
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tatins and Antioxidant Vitamins:
hould Co-Administration Be Avoided?
n the interesting study by Arad et al. (1), co-administration of
torvastatin (20 mg/day) and high-dose antioxidant vitamins C (1 g/
ay) and E (1,000 IU/day) failed to decrease the progression of
oronary calcification, whereas a borderline decrease of cardiovas- rular events was observed. Based on the fact that previous studies
ave shown that statins do decrease both the progression of
oronary artery calcification and cardiovascular events (2), the
nvestigators proposed that the atorvastatin dosage they used was
ow, and they suggested that their population was not large enough
o detect any differences. However, another possibility might be
onsidered: The results of the present study may reflect a negative
ffect of antioxidant vitamins (especially vitamins C and E), which
ould interfere with lipoprotein metabolism, preventing the statin-
nduced increase of high-density lipoprotein (HDL)-2 subfraction,
s has been proposed in the past (3). Indeed, in a study by Brown
t al. (4), it was shown that co-administration of statin and
ntioxidant vitamins C and E partly prevents the beneficial effects
f statins on cardiovascular outcome. Additionally, we (5) have
ecently demonstrated that, although low-dose atorvastatin treat-
ent (10 mg/day) improves endothelial function in patients with
schemic heart disease, this effect is abolished when vitamin E (400
U/day) is co-administered. Therefore, further studies examining
he effect of atorvastatin 10 to 20 mg/day alone on the progression
f coronary artery calcification and clinical events rate are required
efore any conclusion is made.
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EPLY
s Dr. Tousoulis and colleagues point out, the design of the St.
rancis Heart Study Randomized Clinical Trial (two cells of a 2
factorial) does not permit a definitive conclusion as to whether
tatins alone retard the progression of coronary calcification.
owever, there are other reasons to believe that statins do noteduce the rate of coronary calcification, or, if they do, that said
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March 21, 2006:1226–38eduction in the rate of progression is not proportional to their
linical benefit.
First, the study by Achenbach et al. (1), in which patients served
s their own controls, was small (n  66) and neither randomized,
ouble-blind, nor controlled. Contrary to the assertion by Dr.
ousoulis and colleagues that “statins do decrease both the
rogression of coronary calcification and cardiovascular events,”
he study by Achenbach et al. did not report event rates.
Second, with permission of our institutional review board,
onations of atorvastatin and matching placebo from Pfizer, and
nformed consent from 233 participants among those with the
ighest calcium scores, we extended the St. Francis Heart Study
andomized Clinical Trial for another 12 months. Antioxidant
reatment was discontinued, the atorvastatin dose was increased
rom 20 mg daily to 80 mg daily (four 20-mg tablets), and the dose
f placebo was increased from one to four tablets daily. All subjects
emained in their originally assigned group, all continued to receive
spirin 81 mg daily, and all clinical staff remained blinded to
reatment. No differences in baseline characteristics occurred.
Whereas treatment with atorvastatin reduced low-density lipopro-
ein (LDL) cholesterol by 40% in the original randomized clinical
rial, atorvastatin 80 mg daily reduced LDL cholesterol by 49% to
3% (from 144 mg/dl to 67 to 73 mg/dl). As can be seen in Table 1,
owever, 12 months of high-dose atorvastatin without antioxidants
lso failed to retard the process of coronary calcification.
“Baseline” refers to calcium scores in these 233 subjects at the
eginning of the St. Francis Heart Study Randomized Clinical
rial (2). “Exit” refers to their calcium scores at the end of the
riginal randomized clinical trial, and “Exit  1 year” refers to
alcium scores after 12 months of treatment with high-dose
able 1. Changes in Calcium Score, After One Year of
reatment With High-Dose Atorvastatin (80 mg Daily)
r Placebo
Calcium Scores
Treatment Control
p
Value
115 118 —
aseline 530/671/971 550/791/1,034 0.13
xit 960/1,226/1,680 981/1,195/1,706 0.38
Change from baseline 509  323 494  390 0.63
xit  1 yr 1,117/1,427/1,824 1,046/1,337/1,876 0.91
Change from exit 136  194 130  224 0.82
Change from baseline 733  388 712  456 0.71torvastatin or placebo.Values at any point in time were skewed upwards and are
resented as 25th/50th/75th percentiles. Changes in calcium
cores were normally distributed and are presented as mean  SD.
In the recently published Beyond Endorsed Lipid Lowering
ith EBT Scanning (BELLES) study, coronary calcium increased
y similar amounts in groups with one year of intensive and
oderate reduction of LDL-C (47% and 25%, respectively) with
tatin monotherapy (3).
Last but not least, the Heart Protection Study tested simvasta-
in, antioxidants, both, or neither in over 20,000 high-risk subjects
or five years. The antioxidant cocktail (vitamins C, E, and
eta-carotene) neither enhanced nor reduced the benefit of sim-
astatin (4).
In summary, and effects on endothelial function notwithstand-
ng, in randomized clinical trials, statins—alone or in combination
ith antioxidants—have had no effect on the process of coronary
alcification. These findings are consistent not only with the results
f clinical megatrials like the Heart Protection Study, in that
ntioxidant supplements have no effect on atherosclerotic cardio-
ascular disease rates, but with an unexpected result of the St.
rancis Heart Study Randomized Clinical Trial: that calcium
cores and the clinical benefit of statins are dissociated, at least for
s much as four years of therapy.
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